In this novel twist on a medical school staple of the peer-led study group, the Virtual Study Group provides a combination of collaborative and self-directed learning in a multi-interventional curriculum to delve more deeply into the multiple aspects of Multiple Myeloma diagnosis, workup, risk assessment, treatment, and patient care. Led by a local expert faculty, the Virtual Study Group includes cased-based presentations, discussions of clinical studies and expert guidelines as well as local considerations and cultural competencies. Learners will engage in assessments, self-study modules, and group activities, as well as live, online highly interactive meetings. This novel approach to learning complements the Multiple Myeloma webcast and provides deeper absorption of critical clinical information and its context to daily practice.

How to claim credit
Learners have the opportunity to earn up to a total of 2.5 CE for their participation in this small private online course curriculum. Credit will be awarded commensurate with leaner participation in the distinct components of the course curriculum.

Learners who participate in all of the self-study curriculum components are eligible to earn 1.25 CE hours.
Learners who also participate in the Live Group Discussions and the Group Task are eligible to earn additional CE; up to 1.25 CE hours commensurate with participation. These learners will be sent an email with instructions on how to claim this CE credit.

Supporter Acknowledgement
This activity is supported by an educational grant from Sanofi Genzyme, Karyopharm, and Janssen Biotech, Inc.

Self Study

  • Baseline Assessment - Multiple Myeloma

    This baseline assessment is designed to assess learners' knowledge of key clinical concepts in multiple myeloma.

  • Multiple Myeloma - Overview, Disease Continuum, Recent Guideline Updates

    This module provides an overview of multiple myeloma (MM), including disease burden and features and epidemiology. The module also discusses recent updates to the MM clinical practice guidelines from the NCCN/ASCO/CCO/IMWG regarding diagnosis and treatment of patients with MM.

  • Recently Approved Anti-Myeloma Agents

    This module covers data for the new agents that have gained regulatory approval in MM in the past 5 years, including daratumumab, elotuzumab, selinexor, ixazomib, and panobinostat. Isatuximab, approved in March 2020, is discussed in the third self-study module.

  • Emerging Agents and Evolving Concepts in Multiple Myeloma

    This module provides an overview of emerging agents and isatuximab, which was approved by the FDA in March 2020. Evolving concepts including minimal residual disease, molecular/genomics assessments, role of stem cell transplant, and personalization of MM care are also reviewed.

  • Final Self Assessment - Multiple Myeloma

    This final assessment is designed to evaluate your clinical knowledge of key concepts in MM, after completing the learning activities in the virtual study group.

Live Group Discussions

  • Group Discussion 1: Review of Advances Across the Multiple Myeloma Continuum

    This live discussion will offer an interactive session to discuss recent advances across the myeloma care and management continuum, including particularly challenging or emerging aspects that impact the care and management of MM patients in your practice. This is an opportunity to gain practical insights and perspectives in the care of your patients with multiple myeloma.

    Please read the Activity, Faculty and CE information in the Resources section.

  • Group Discussion 2: Group Task Review

    This Live Web Conference will target practical strategies for applying some of the information discussed in the modules and in our previous Group Discussions by focusing on the Group Task to which you all contributed. We will discuss your submitted responses and the comments that you posted and welcome everyone’s participation.

    Please read the Activity, Faculty and CE information in the Resources section.

Group Challenge

  • Case Study: Refractory/Relapsed Multiple Myeloma

    This case study is focused on application of knowledge of optimal response monitoring criteria and treatment options to draft a care plan for a patient with refractory/relapsed MM.

  • Case Study: Treatment Personalization in Heavily Pretreated Myeloma

    This case study focuses on applying knowledge of emerging agents in MM and approaches to personalize treatment of a heavily pretreated patient with relapsed/refractory MM.

Curriculum is Currently Closed

Thank you for your interest. Currently, the curriculum is closed for enrollment but we encourage you to keep an eye out for future opportunities or alternative programs that might align with your educational goals.

View Other Offerings

Completed Groups

Pamela Dudkiewicz, DNP
Nurse Practitioner
Karolina Faysman, NP
Lead Nurse Practitioner
Tiffany Richards, PhD
Nurse Practitioner
Amie Fonder, PA-C
Instructor in Medicine
Teresa Fogaren, MSN, AGNP-C
Nurse Practitioner
Nurse Practitioner, Cleveland Clinic
Daniel Verina, DNP
Nurse Practitioner
Kevin Brigle, PhD, NP
Oncology Nurse Practitioner